S&P 500
(0.86%) 5 248.49 points
Dow J
(1.22%) 39 760 points
Nasdaq
(0.51%) 16 400 points
Oil
(1.25%) $82.37
Gas
(1.05%) $1.736
Gold
(0.71%) $2 228.50
Silver
(-0.19%) $24.71
Platinum
(0.99%) $918.75
USD/EUR
(0.19%) $0.925
USD/NOK
(0.56%) $10.83
USD/GBP
(-0.04%) $0.791
USD/RUB
(0.16%) $92.59

Realtime updates for Nektar Therapeutics [NKTR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated28 Mar 2024 @ 10:06

1.09% $ 0.895

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 10:06):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally...

Stats
Today's Volume 50 521.00
Average Volume 1.62M
Market Cap 164.30M
EPS $0 ( 2024-03-04 )
Next earnings date ( $-0.200 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.620
ATR14 $0.00200 (0.22%)
Insider Trading
Date Person Action Amount type
2024-03-05 Deep Track Capital, Lp Buy 0 Common Stock
2024-02-20 Zalevsky Jonathan Sell 9 014 Common Stock
2024-02-20 Wilson Mark Andrew Sell 7 606 Common Stock
2024-02-20 Robin Howard W Sell 20 033 Common Stock
2023-12-13 Zalevsky Jonathan Buy 250 000 Stock Option
INSIDER POWER
84.81
Last 97 transactions
Buy: 6 976 063 | Sell: 637 451

Volume Correlation

Long: -0.17 (neutral)
Short: 0.79 (moderate)
Signal:(53.376) Neutral

Nektar Therapeutics Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nektar Therapeutics Correlation - Currency/Commodity

The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.77
( moderate negative )

Nektar Therapeutics Financials

Annual 2023
Revenue: $90.12M
Gross Profit: $53.48M (59.34 %)
EPS: $-1.450
Q4 2023
Revenue: $23.89M
Gross Profit: $16.60M (69.51 %)
EPS: $-0.220
Q3 2023
Revenue: $24.14M
Gross Profit: $11.71M (48.51 %)
EPS: $-0.240
Q2 2023
Revenue: $20.50M
Gross Profit: $13.51M (65.88 %)
EPS: $-0.270

Financial Reports:

No articles found.

Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators